Nuveen’s LENZ Therapeutics LENZ Stock Holding History

Nuveen’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$265K	Buy	46,633 +6,443	+16%	+$51.9K	﹤0.01%	3543
2026 Q1	$368K	Buy	40,190 +285	+0.7%	+$4K	﹤0.01%	2951
2025 Q4	$638K	Sell	39,905 -245,638	-86%	-$7.16M	﹤0.01%	2783
2025 Q3	$13.3M	Buy	285,543 +107,329	+60%	+$3.95M	﹤0.01%	1391
2025 Q2	$5.22M	Buy	178,214 +111,177	+166%	+$3.02M	﹤0.01%	1850
2025 Q1	$1.72M	Buy	67,037 +43,907	+190%	+$1.08M	﹤0.01%	2391
2024 Q4	$668K	Hold	23,130	–	–	﹤0.01%	2880
2024 Q3	$549K	Hold	23,130	–	–	﹤0.01%	2984
2024 Q2	$400K	Buy	+23,130	New	+$404K	﹤0.01%	3064
2024 Q1	–	Sell	-5,677	Closed	-$104K	–	3308
2023 Q4	$104K	Hold	5,677	–	–	﹤0.01%	3283
2023 Q3	$98.5K	Hold	5,677	–	–	﹤0.01%	3124
2023 Q2	$103K	Buy	+5,677	New	+$113K	﹤0.01%	3162
2022 Q2	–	Sell	-7,744	Closed	-$373K	–	3514
2022 Q1	$373K	Buy	7,744 +4,380	+130%	+$274K	﹤0.01%	3081
2021 Q4	$240K	Sell	3,364 -1,538	-31%	-$127K	﹤0.01%	3213
2021 Q3	$562K	Buy	+4,902	New	+$726K	﹤0.01%	3147

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

7IH

72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Nuveen's LENZ Position: Q2 2026 in Review

Nuveen increased its LENZ Therapeutics (LENZ) stake by 16% in Q2 2026, buying an estimated $51.9K and bringing the position to 46,633 shares worth $265K. The position accounts for ﹤0.01% of the portfolio, ranked #3543.

Nuveen first reported a position in LENZ in Q3 2021 and has held it in 15 quarters since. The position peaked at $13.3M in Q3 2025. 144 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

Nuveen held 46,633 shares of LENZ Therapeutics worth $265K as of Q2 2026.
Nuveen bought 6,443 LENZ Therapeutics shares in Q2 2026, an estimated $51.9K.
LENZ Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3543 holding.
Nuveen first reported a position in LENZ Therapeutics in Q3 2021 and has held it in 15 quarters since.
Nuveen's LENZ Therapeutics position peaked at $13.3M in Q3 2025.
144 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.